高通量荧光成像技术在新药发现中的应用综述。

IF 6 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Expert Opinion on Drug Discovery Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI:10.1080/17460441.2025.2499123
Michael Ronzetti, Anton Simeonov
{"title":"高通量荧光成像技术在新药发现中的应用综述。","authors":"Michael Ronzetti, Anton Simeonov","doi":"10.1080/17460441.2025.2499123","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>High-throughput fluorescence imaging (HTFI) is revolutionizing drug discovery by enabling rapid and precise detection of biological targets and cellular processes. Recent advances in fluorescence imaging technologies now provide unprecedented sensitivity, resolution, and throughput. Integration of artificial intelligence (AI) and machine learning (ML) into HTFI workflows significantly enhances data processing, aiding in hit identification, pattern recognition, and mechanistic understanding.</p><p><strong>Areas covered: </strong>This review outlines recent technological developments, integration strategies, and emerging applications of HTFI. It emphasizes HTFI's role in phenotypic screening, especially for complex diseases such as cancer, neurodegenerative disorders, and viral infections. Additionally, it highlights advances in 3D culture systems, organoids, and organ-on-a-chip technologies, which facilitate physiologically relevant testing, improved predictive accuracy, and translational potential, alongside innovative molecular probes and biosensors.</p><p><strong>Expert opinion: </strong>Despite its advancements, HTFI faces ongoing challenges, including data standardization, integration with multi-omics approaches, and scalability of advanced models. However, recent progress in organoid and 3D modeling technologies has enhanced the physiological relevance of HTFI assays, complemented by sophisticated AI and ML-driven data analysis techniques.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"785-797"},"PeriodicalIF":6.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105877/pdf/","citationCount":"0","resultStr":"{\"title\":\"A comprehensive update on the application of high-throughput fluorescence imaging for novel drug discovery.\",\"authors\":\"Michael Ronzetti, Anton Simeonov\",\"doi\":\"10.1080/17460441.2025.2499123\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>High-throughput fluorescence imaging (HTFI) is revolutionizing drug discovery by enabling rapid and precise detection of biological targets and cellular processes. Recent advances in fluorescence imaging technologies now provide unprecedented sensitivity, resolution, and throughput. Integration of artificial intelligence (AI) and machine learning (ML) into HTFI workflows significantly enhances data processing, aiding in hit identification, pattern recognition, and mechanistic understanding.</p><p><strong>Areas covered: </strong>This review outlines recent technological developments, integration strategies, and emerging applications of HTFI. It emphasizes HTFI's role in phenotypic screening, especially for complex diseases such as cancer, neurodegenerative disorders, and viral infections. Additionally, it highlights advances in 3D culture systems, organoids, and organ-on-a-chip technologies, which facilitate physiologically relevant testing, improved predictive accuracy, and translational potential, alongside innovative molecular probes and biosensors.</p><p><strong>Expert opinion: </strong>Despite its advancements, HTFI faces ongoing challenges, including data standardization, integration with multi-omics approaches, and scalability of advanced models. However, recent progress in organoid and 3D modeling technologies has enhanced the physiological relevance of HTFI assays, complemented by sophisticated AI and ML-driven data analysis techniques.</p>\",\"PeriodicalId\":12267,\"journal\":{\"name\":\"Expert Opinion on Drug Discovery\",\"volume\":\" \",\"pages\":\"785-797\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105877/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Discovery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17460441.2025.2499123\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2025.2499123","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

高通量荧光成像(HTFI)是革命性的药物发现通过实现快速和精确的检测生物靶点和细胞过程。荧光成像技术的最新进展提供了前所未有的灵敏度、分辨率和通量。将人工智能(AI)和机器学习(ML)集成到HTFI工作流程中可以显著增强数据处理,有助于命中识别、模式识别和机制理解。涵盖领域:本综述概述了HTFI的最新技术发展、集成策略和新兴应用。它强调HTFI在表型筛查中的作用,特别是对于复杂的疾病,如癌症、神经退行性疾病和病毒感染。此外,它还强调了3D培养系统,类器官和器官芯片技术的进步,这些技术促进了生理学相关测试,提高了预测准确性和转化潜力,以及创新的分子探针和生物传感器。专家意见:尽管取得了进步,但HTFI仍面临着持续的挑战,包括数据标准化、与多组学方法的集成以及高级模型的可扩展性。然而,类器官和3D建模技术的最新进展增强了HTFI分析的生理相关性,并辅以复杂的人工智能和机器学习驱动的数据分析技术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A comprehensive update on the application of high-throughput fluorescence imaging for novel drug discovery.

Introduction: High-throughput fluorescence imaging (HTFI) is revolutionizing drug discovery by enabling rapid and precise detection of biological targets and cellular processes. Recent advances in fluorescence imaging technologies now provide unprecedented sensitivity, resolution, and throughput. Integration of artificial intelligence (AI) and machine learning (ML) into HTFI workflows significantly enhances data processing, aiding in hit identification, pattern recognition, and mechanistic understanding.

Areas covered: This review outlines recent technological developments, integration strategies, and emerging applications of HTFI. It emphasizes HTFI's role in phenotypic screening, especially for complex diseases such as cancer, neurodegenerative disorders, and viral infections. Additionally, it highlights advances in 3D culture systems, organoids, and organ-on-a-chip technologies, which facilitate physiologically relevant testing, improved predictive accuracy, and translational potential, alongside innovative molecular probes and biosensors.

Expert opinion: Despite its advancements, HTFI faces ongoing challenges, including data standardization, integration with multi-omics approaches, and scalability of advanced models. However, recent progress in organoid and 3D modeling technologies has enhanced the physiological relevance of HTFI assays, complemented by sophisticated AI and ML-driven data analysis techniques.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
10.20
自引率
1.60%
发文量
78
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信